Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

241.50 -1.40 (-0.58%) At close: 05:29PM CEST

Swedish Orphan Biovitrum AB (publ)

Tomtebodavägen 23A
Solna 112 76
Sweden
46 86 97 20 00
https://www.sobi.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 1,555

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Guido Oelkers	CEO & Pres	23.4M	N/A	1965
Mr. Henrik Stenqvist	Chief Financial Officer	N/A	N/A	1968
Ms. Christine Wesstrom	Head of Technical Operations	N/A	N/A	1975
Mr. Thomas Kudsk Larsen	Head of Communication & Investor Relations	N/A	N/A	1974
Mr. Torbjörn Hallberg	Gen. Counsel and Head of Legal Affairs & HR	N/A	N/A	1969
Mr. Daniel Rankin	Head of Strategy & Corp. Devel.	N/A	N/A	1980
Pablo de Mora	Head of Global Marketing & Access	N/A	N/A	1968
Ms. Lena Bjurner	Head of HR	N/A	N/A	1968
Mr. Philip Wood	Head of Haematology	N/A	N/A	1968
Ms. Konstantina Karampela	Sr. Director of European Commercial Operations (Specialty Care and Partner Products)	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Corporate governance

Swedish Orphan Biovitrum AB (publ)’s ISS governance QualityScore as of 1 February 2023 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.